A5101811382- Chronic Lymphocytic Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Lymphoma Diagnosis and Treatment
- CAR-T cell therapy research
- Acute Lymphoblastic Leukemia research
- Histone Deacetylase Inhibitors Research
- Acute Myeloid Leukemia Research
- Eosinophilic Disorders and Syndromes
- Immunotherapy and Immune Responses
- Immunodeficiency and Autoimmune Disorders
- Immune Cell Function and Interaction
- Protein Degradation and Inhibitors
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Monoclonal and Polyclonal Antibodies Research
- Advanced Breast Cancer Therapies
- Epigenetics and DNA Methylation
- Peptidase Inhibition and Analysis
- Ubiquitin and proteasome pathways
- Immune cells in cancer
- Multiple Myeloma Research and Treatments
- Glycosylation and Glycoproteins Research
- Cancer Immunotherapy and Biomarkers
- PI3K/AKT/mTOR signaling in cancer
- Chemotherapy-induced cardiotoxicity and mitigation
- Click Chemistry and Applications
Moffitt Cancer Center
2016-2025
University of South Florida
2010-2023
Wellcome Sanger Institute
2019
Exelis (United States)
2016
Florida College
2013
GlaxoSmithKline (United States)
2012
GlaxoSmithKline (India)
2010-2012
Fox Chase Cancer Center
2012
The University of Texas MD Anderson Cancer Center
2012
Nebraska Medical Center
2012
Ponatinib is a potent oral tyrosine kinase inhibitor of unmutated and mutated BCR-ABL, including BCR-ABL with the inhibitor–refractory threonine-to-isoleucine mutation at position 315 (T315I). We conducted phase 2 trial ponatinib in patients chronic myeloid leukemia (CML) or Philadelphia chromosome–positive acute lymphoblastic (Ph-positive ALL).
The BCL2 inhibitor venetoclax has shown activity in patients with chronic lymphocytic leukemia (CLL), but its efficacy combination other agents CLL and coexisting conditions is not known.In this open-label, phase 3 trial, we investigated fixed-duration treatment obinutuzumab previously untreated conditions. Patients a score of greater than 6 on the Cumulative Illness Rating Scale (scores range from 0 to 56, higher scores indicating more impaired function organ systems) or calculated...
Among Bruton's tyrosine kinase inhibitors, acalabrutinib has greater selectivity than ibrutinib, which we hypothesized would improve continuous therapy tolerability. We conducted an open-label, randomized, noninferiority, phase III trial comparing and ibrutinib in patients with chronic lymphocytic leukemia (CLL).
CD19 CAR T-cell therapy with axicabtagene ciloleucel (axi-cel) for relapsed or refractory (R/R) large B cell lymphoma (LBCL) may lead to durable remissions, however, prolonged cytopenias and infections occur. In this single center retrospective study of 85 patients, we characterized immune reconstitution patients remaining in remission after axi-cel LBCL. Prolonged (those occurring at day 30 following infusion) were common >= grade 3 neutropenia seen 21/70 (30-0%) persisting 3/31 (9-7%) 1...
Abstract High metabolic tumor volume (MTV) predicts worse outcomes in lymphoma treated with chemotherapy. However, it is unknown if this holds for patients axicabtagene ciloleucel (axi-cel), an anti-CD19 targeted chimeric antigen receptor T-cell therapy. The primary objective of retrospective study was to investigate the relationship between MTV and survival (overall [OS] progression-free [PFS]) relapsed/refractory large B-cell (LBCL) axi-cel. Secondary objectives included finding...
Ponatinib, the only approved all known-BCR::ABL1 inhibitor, is a third-generation tyrosine-kinase inhibitor (TKI) designed to inhibit BCR::ABL1 with or without any single resistance mutation, including T315I, and induced robust durable responses at 45 mg/day in patients CP-CML resistant second-generation TKIs PACE trial. However, cardiovascular toxicities, arterial occlusive events (AOEs), have emerged as treatment-related AEs within this class of TKIs. The OPTIC trial evaluated efficacy...
OverviewChronic myelogenous leukemia (CML) accounts for 15% of adult leukemias.Although the median age disease onset is 67 years, CML occurs in all groups (Surveillance, Epidemiology, and End Results [SEER] statistics).In 2009, an estimated 5050 cases will be diagnosed 470 patients die from United States. 1 a hematopoietic stem cell disease, which characterized by reciprocal translocation between chromosomes 9 22, resulting formation Philadelphia chromosome (Ph chromosome).This t(9;22)...
Activation of the ER stress response is associated with malignant progression B cell chronic lymphocytic leukemia (CLL). We developed a murine CLL model that lacks stress–associated transcription factor XBP-1 in cells and found deficiency decelerates CLL-associated disease. resulted acquisition phenotypes are disadvantageous for leukemic survival, including compromised BCR signaling capability increased surface expression sphingosine-1-phosphate receptor 1 (S1P1). Because requires RNase...
Histone deacetylases (HDACs), originally described as histone modifiers, have more recently been demonstrated to target a variety of other proteins unrelated the chromatin environment. In this context, our present work demonstrates that pharmacological or genetic abrogation HDAC6 in primary melanoma samples and cell lines, down‐regulates expression PD‐L1, an important co‐stimulatory molecule expressed cancer cells, which activates inhibitory regulatory pathway PD‐1 T‐cells. Our data suggests...
Abstract Imatinib mesylate is a potent, molecularly targeted therapy against the oncogenic tyrosine kinase BCR-ABL. Although imatinib has considerable efficacy chronic myeloid leukemia (CML), advanced-stage CML patients frequently become refractory to this agent. The bone marrow predominant microenvironment of and rich source both soluble factors extracellular matrices, which may influence drug response. To address on sensitivity, we used an in vitro stroma model. Our data show culturing...
Histone deacetylases (HDACs) are involved in diverse cellular regulatory mechanisms including non-canonical functions outside the chromatin environment. Several publications have demonstrated that selective HDAC inhibitors (HDACi) can influence tumor immunogenicity and functional activity of specific immune cells. In particular, inhibition HDAC6 has been reported to decrease growth several malignancies. However, there is still no clarity about components mediating this effect. study, we...
The median survival for metastatic melanoma is in the realm of 8–16 months and there are few therapies that offer significant improvement overall survival. One recent advances cancer treatment focuses on epigenetic modifiers to alter survivability immunogenicity cells. Our group others have previously demonstrated pan‐HDAC inhibitors induce apoptosis, cell cycle arrest changes Here we interrogated specific HDACs which may be responsible this effect. We found both genetic abrogation...
Immune dysregulation and altered T‐cell hemostasis play important roles in the pathogenesis of myelodysplastic syndromes (MDS). Recent studies suggest an increased risk MDS among patients with autoimmune diseases. Here, we investigated prevalence diseases patients, comparing characteristics outcomes those without From our study group 1408 391 (28%) had disease, hypothyroidism being most common type, accounting for 44% ( n = 171) (12% all analyzed). Other ≥5% included idiopathic...